目的:探究奥硝唑与改良负压封闭引流(vacuum sealing drainage,VSD)联合治疗口腔颌面部间隙感染(oral and maxillofacial space infections,OMSI)患者临床效果及对血清白细胞计数(white blood cell count,WBC)、中性粒细胞计数(neutroph...目的:探究奥硝唑与改良负压封闭引流(vacuum sealing drainage,VSD)联合治疗口腔颌面部间隙感染(oral and maxillofacial space infections,OMSI)患者临床效果及对血清白细胞计数(white blood cell count,WBC)、中性粒细胞计数(neutrophil count,NEUT)的影响。方法:回顾性分析2020年1月~2022年6月于我院接受奥硝唑联合传统切开引流术治疗的40例OMSI患者临床资料,纳入对照组;同期于我院接受奥硝唑联合改良VSD治疗的40例OMSI患者临床资料,纳入观察组。比较两组患者临床疗效(创口愈合时间、肉芽生长时间、住院时间)、术前和术后1周症状[脓肿直径、疼痛(Wong-Baker面部表情量表)、张口度])、血清因子[WBC、NEUT、降钙素原(procalcitonin,PCT)]水平,记录两组患者1周内并发症(感染、败血症、纵膈炎、心力衰竭)发生情况。结果:观察组患者住院时间、创口愈合时间、肉芽生长时间均短于对照组(P<0.05);术后1周,两组患者脓肿直径、Wong-Baker评分、WBC、NEUT、PCT水平均较术前降低,且观察组低于对照组(P<0.05),而张口度较治疗前增大,观察组大于对照组(P<0.05);术后1周内,观察组并发症发生率低于对照组(P<0.05)。结论:奥硝唑联合改良VSD治疗OMSI效果显著,可改善患者临床症状,缓解炎症反应,减少并发症发生。展开更多
Background The SLAM family recently has been reported to show an important biological role in lymphocyte development and immunological function, and it is efficient to highly purify hematopoietic stem cells using a si...Background The SLAM family recently has been reported to show an important biological role in lymphocyte development and immunological function, and it is efficient to highly purify hematopoietic stem cells using a simple combination of SLAM family members. To elucidate the presence of this family on acute lymphoblastic leukemia （ALL）,as well as its relationship with the leukemia-initiating potential, we analyzed the expression pattern of this family members on human ALL progenitor cells, combined with serial xenotransplantation assay.Methods Expression analysis was carried out by flow cytometry. We combined the expression pattern of human CD150,CD244 and CD48 with serial xenotransplantation of B-ALL progenitor cells to indicate their relationship.Results CD48 and CD244 were expressed on most B-ALL progenitor cells, the percentage being （93.08±6.46）% and （63.37±29.31）%, respectively. Interestingly, the proportion of CD150＋ cells declined obviously in engrafted cases （（24.94±7.32）%） compared with non-engrafted cases （（77.54±5.93）%, P 〈0.01）, which indicated that only blast cells with low percentage of CD150＋ population were able to reconstitute leukemia into primary, secondary and tertiary NOD/SCID mice.Conclusions SLAM family members are present on B-ALL progenitor cells and the leukemia-initiating potential of leukemic blasts is correlated negatively with the proportion of CD150＋ cells, the percentage of which can serve as a useful predictor for engraftment success of B-ALL to immune deficient mice.展开更多
文摘Background The SLAM family recently has been reported to show an important biological role in lymphocyte development and immunological function, and it is efficient to highly purify hematopoietic stem cells using a simple combination of SLAM family members. To elucidate the presence of this family on acute lymphoblastic leukemia （ALL）,as well as its relationship with the leukemia-initiating potential, we analyzed the expression pattern of this family members on human ALL progenitor cells, combined with serial xenotransplantation assay.Methods Expression analysis was carried out by flow cytometry. We combined the expression pattern of human CD150,CD244 and CD48 with serial xenotransplantation of B-ALL progenitor cells to indicate their relationship.Results CD48 and CD244 were expressed on most B-ALL progenitor cells, the percentage being （93.08±6.46）% and （63.37±29.31）%, respectively. Interestingly, the proportion of CD150＋ cells declined obviously in engrafted cases （（24.94±7.32）%） compared with non-engrafted cases （（77.54±5.93）%, P 〈0.01）, which indicated that only blast cells with low percentage of CD150＋ population were able to reconstitute leukemia into primary, secondary and tertiary NOD/SCID mice.Conclusions SLAM family members are present on B-ALL progenitor cells and the leukemia-initiating potential of leukemic blasts is correlated negatively with the proportion of CD150＋ cells, the percentage of which can serve as a useful predictor for engraftment success of B-ALL to immune deficient mice.
